Document Detail


Serial analysis of soluble intercellular adhesion molecule-1 level in relapsing-remitting multiple sclerosis patients during IFN-beta1b treatment.
MedLine Citation:
PMID:  12716484     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In this controlled study, we investigated the serum and cerebrospinal fluid (CSF) levels of soluble intercellular adhesion molecule-1 (sICAM-1) in relapsing-remitting multiple sclerosis (RRMS) patients and changes in the levels of this adhesion molecule during interferon-beta1b (IFN-beta1b) treatment. We also investigated the changes in the levels of sICAM-1 in correlation with disease activity and with findings on magnetic resonance images (MRI). The study included 24 patients (16 females and 8 males) who were confirmed to have RRMS based on the criteria of Poser et al. Sixteen of the patients received IFN-beta1b (Betaseron, Berlex Laboratories, Schering AG Germany, Berlin) treatment, and 8 did not receive this therapy. The levels of sICAM-1 in the MS patients' serum and CSF were significantly higher than levels in individuals with noninflammatory neurologic disease (p = 0.0081 and p = 0.0001, respectively). In the first 3 months of the study, MS patients treated with IFN-beta1b showed a significant rise in sICAM-1 levels (p = 0.0023), whereas their untreated counterparts showed no significant change. Neither of the groups showed a significant correlation between sICAM-1 level and disease activity demonstrated by MRI or between sICAM-1 level and clinical disease activity. The findings suggest that IFN-beta1b treatment may have a short-term upregulating effect on sICAM-1.
Authors:
Munire Kilinc; Isil Saatci-Cekirge; Rana Karabudak
Related Documents :
2903464 - Sardinian multiple sclerosis is associated with hla-dr4: a serologic and molecular anal...
18283394 - Clinical characteristics of patients with late-onset multiple sclerosis.
19383644 - Vitamin d status and effect of low-dose cholecalciferol and high-dose ergocalciferol su...
19354094 - Multiple sclerosis presenting with erotomanic delusions in the context of "don't ask, d...
19915854 - Diffusion tensor tractography detection of functional pathway for the spread of epilept...
2044924 - Sensitivity of the gastric mucosa to acid and duodenal contents in patients with nonulc...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research     Volume:  23     ISSN:  1079-9907     ISO Abbreviation:  J. Interferon Cytokine Res.     Publication Date:  2003 Mar 
Date Detail:
Created Date:  2003-04-28     Completed Date:  2003-11-07     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9507088     Medline TA:  J Interferon Cytokine Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  127-33     Citation Subset:  IM    
Affiliation:
Neurology Department, Baskent University Hospital, Ankara, Turkey. munirekilinc@superonline.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Enzyme-Linked Immunosorbent Assay
Female
Humans
Intercellular Adhesion Molecule-1 / blood*,  cerebrospinal fluid
Interferon-beta / therapeutic use*
Magnetic Resonance Imaging
Male
Middle Aged
Multiple Sclerosis / blood,  drug therapy*,  pathology
Recurrence
Solubility
Time Factors
Chemical
Reg. No./Substance:
126547-89-5/Intercellular Adhesion Molecule-1; 145155-23-3/interferon beta-1b; 77238-31-4/Interferon-beta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of oxidized low-density lipoprotein on differential gene expression in primary human endothel...
Next Document:  Association of HLA alleles with response (especially biochemical response) to interferon therapy in ...